CLAIMS

WHAT IS CLAIMED IS:

1. A crystalline salt of *(S)*-3-[*(S)*-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine and hydrochloric acid in a 1:1 molar ratio, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.78±0.20, 15.26±0.20, 19.08±0.20, 20.36±0.20, 21.50±0.20, and 25.46±0.20.

2. The compound of Claim 1, characterized by having one or more additional diffraction peaks at 2θ values selected from 26.42±0.20, 30.65±0.20, 28.91±0.20, 24.77±0.20, 14.42±0.20, 16.74±0.20, and 5.20±0.20.

~~3. The compound as claimed in any one of Claims 1 to 2, characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1.~~

43. The compound as claimed in any one of Claims 1 to 32, characterized by a differential scanning calorimetry trace which has a melting point of about 128°C.

~~5. The compound as claimed in any one of Claims 1 to 4, characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 2.~~

64. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound as claimed in any one of Claims 1 to 53.

75. The pharmaceutical composition of Claim 46, further comprising a secondary therapeutic agent selected from anti-Alzheimer's agents, anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof.

86. A process for preparing the compound as claimed in any one of Claims 1 to 53,

comprising the step of:

(a) treating a hydrochloride salt of *(S)*-3-[*(S)*-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine with a polar solvent to form a first composition or deprotecting *(S)*-3-[*(S)*-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine-1-carboxylic acid *t*-butyl ester with hydrochloric acid in an inert diluent to form a first composition; and (b) adding a nonpolar solvent to form a second composition from which the compound as claimed in any one of Claims 1 to ~~5~~ 3 is formed.

~~9~~7. The process of Claim ~~8~~6, wherein step (b) comprises:

(i) adding a non-polar solvent to form a second composition;

(ii) optionally cooling to effect crystallization; and

(iii) isolating the resulting solids to yield the compound.

~~10~~8. The process as claimed in any one of Claims ~~8~~6 to ~~9~~7, wherein the polar solvent is isopropanol.

~~11~~9. The process as claimed in any one of Claims ~~8~~6 to ~~9~~7, wherein deprotection is done with 3 M HCl and the inert diluent is cyclopentyl methyl ether.

~~12~~10. The process as claimed in any one of Claims ~~8~~6 to ~~9~~7, wherein the nonpolar solvent is diisopropyl ether.

~~13. A process for purifying *(S)*-3-[*(S)*-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine comprising preparing the compound as claimed in any one of Claims 1 to 5.~~

~~14~~11. A compound as claimed in any one of Claims 1 to ~~5~~3, for use in therapy.

~~15~~12. The compound of Claim ~~14~~11, for treating a pain disorder, a depressive disorder, an affective disorder, attention deficit hyperactivity disorder~~, a cognitive disorder~~, stress urinary incontinence, chronic fatigue syndrome, obesity, or vasomotor symptoms associated with menopause.

~~16~~13. The compound of Claim ~~15~~12, wherein the pain disorder is selected from neuropathic

pain, fibromyalgia, chronic low back pain, and osteoarthritis.

~~17~~14. Medicament containing a compound as claimed in any one of Claims 1 to ~~5~~3.

~~18~~15. Use of a compound as claimed in any one of Claims 1 to ~~5~~3 for the manufacture of a medicament.

~~19~~16. The use of Claim ~~18~~15, wherein the medicament is for the treatment of a pain disorder, a depressive disorder, an affective disorder, attention deficit hyperactivity disorder, ~~a cognitive disorder,~~ stress urinary incontinence, chronic fatigue syndrome, obesity, or vasomotor symptoms associated with menopause.